PROK ProKidney Corp.
USHealthcareAs of 2026-10-08
Why PROK matters now
ProKidney Corp. (PROK) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.66 with +5.73% on the session and $558.2M in market capitalization; recent performance reads 1-month +18.06% and YTD -18.30%.
The latest financial table shown here is Q1 2026, with revenue of $226.0K, net income of $-22.6M, and EPS of $-0.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.4%.
The latest indexable market news headline is "ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.00; recent insider activity includes Girolamo Todd C filing C-Conversion. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.25
P/S
692.18
EV/EBITDA
-3.44
DCF Value
$0.87
FCF Yield
-24.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-224.4%
Operating Margin
-18959.7%
Net Margin
-8418.0%
ROE
7.4%
ROA
-25.6%
ROIC
-54.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $226.0K | $-22.6M | $-0.16 |
| Q4 2025 | $225.0K | $-19.2M | $-0.14 |
| FY 2025 | $893.0K | $-69.0M | $-0.52 |
| Q3 2025 | $217.0K | $-16.5M | $-0.12 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$4.67
Target (Median)
$5.00
Target Range
$3.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.70
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.